文献速递妇科

复发性卵巢癌三次减瘤术的更新扩展分析

Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
PubMed 文献 · Gynecol Oncol · 2021-05-25

该回顾性研究纳入1990至2019年间在本机构接受三次减瘤术的114例复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌患者,其中79例(69.2%)为高级别浆液性肿瘤。完全肉眼切除、无治疗间期和铂敏感性均与疾病特异性生存显著相关,且在多变量分析中保持显著。高级别浆液性卵巢癌、单一复发部位且距二次减瘤术≥2年的患者生存期最长(中位DSS 79.5个月)。

要点

  • 完全肉眼切除、较长无治疗间期和铂敏感与三次减瘤术后疾病特异性生存改善显著相关。
  • 高级别浆液性卵巢癌、单一复发部位且距二次减瘤术≥2年的患者中位DSS达79.5个月。
  • 术后治疗与生存差异无关,患者选择对三次减瘤术获益至关重要。

核心结论

  • 三次减瘤术应严格选择患者,达到完全肉眼切除者可能获益最大。
  • 铂敏感和较长无治疗间期也与疾病特异性生存改善相关。
  • 高级别浆液性卵巢癌、单一复发部位且距二次减瘤术≥2年的患者生存期最长。

研究设计与样本

  • 回顾性识别1990年1月1日至2019年1月1日在本机构接受三次减瘤术的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌患者,共114例。
  • 采用Kaplan-Meier曲线估计生存并用log-rank检验比较,Cox比例风险回归检测与生存相关的变量。

主要发现

  • 114例中79例(69.2%)为高级别浆液性肿瘤;66例有基因检测结果者中22例(33%)携带胚系或体细胞BRCA突变。
  • 完全肉眼切除、无治疗间期和铂敏感性均与疾病特异性生存显著相关,多变量分析HR分别为3.71(95%CI: 1.59-8.70)、0.49(95%CI: 0.28-0.85)和2.94(95%CI: 1.22-7.07)。
  • 术后治疗与生存差异无关。
  • 高级别浆液性卵巢癌、单一复发部位且距二次减瘤术≥2年的患者中位DSS为79.5个月。

临床怎么用

  • 对复发性卵巢癌考虑三次减瘤术时,应综合评估能否达到完全肉眼切除、铂敏感性和无治疗间期以选择获益人群。
  • 高级别浆液性卵巢癌、单一复发部位且距二次减瘤术≥2年的患者可优先考虑三次减瘤术。

局限性

  • 本研究为单中心回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to describe clinicopathologic and surgical factors associated with oncologic outcomes in patients undergoing tertiary cytoreduction and to present a clinical model to identify patients with high-grade serous ovarian cancer (HGSOC) who may benefit most from tertiary cytoreduction. METHODS: We retrospectively identified patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who underwent tertiary cytoreduction at our institution from 1/1/1990-1/1/2019. Kaplan-Meier curves were used to estimate survival and compared using the log-rank test. Cox-proportional hazards regression was used to detect variables associated with survival. RESULTS: Of 114 patients who met inclusion criteria, 79 (69.2%) had high-grade serous tumors. Of patients with available genetic testing (n = 66), 22 (33%) harbored germline or somatic BRCA mutations. Fifty-eight women (50.9%) died of disease. Complete gross resection (CGR) at tertiary cytoreduction, treatment-free interval (TFI), and platinum sensitivity were all significantly associated with disease-specific survival (DSS) and maintained significance on multivariate analysis (HR 3.71, 95% CI: 1.59-8.70; HR 0.49, 95% CI: 0.28-0.85; and HR 2.94, 95% CI: 1.22-7.07, respectively). Postoperative treatment was not associated with a survival difference. Patients with HGSOC and a single site of recurrence who were ≥2 years from secondary cytoreduction had the longest survival after tertiary cytoreduction (median DSS, 79.5 months). CONCLUSIONS: Proper patient selection for tertiary cytoreduction is essential. Those who achieve CGR likely derive the greatest benefit from tertiary surgery. Platinum sensitivity and prolonged TFI are also associated with improved DSS. Patients with HGSOC and single-site recurrence who were ≥2 years out from secondary cytoreduction had the longest DSS.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Manning-Geist BL, Chi DS, Long Roche K, et al. Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. Gynecol Oncol. 2021. PMID: 34045053. doi:10.1016/j.ygyno.2021.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。